Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention
Section snippets
HFE gene and protein
HH was identified in the 1970s as a disorder linked to a genetic locus on the short arm of chromosome 6 and inherited in an autosomal-recessive fashion [8]. Feder et al [9] subsequently identified a novel gene called HFE in the HLA region of chromosome 6. This gene encodes a major histocompatibility complex class 1–like protein that binds to β2-microglobulin (like other major histocompatibility complex class 1 molecules) and interacts with TfR-1 [10], [11], [12], [13]. Several missense
Pathophysiology of hemochromatosis
The primary defect in HFE-related HH is an increase in intestinal iron absorption relative to body iron stores [14], [15], [18], [19]. The villus enterocytes of the duodenum (Fig. 1) are responsible for iron absorption. Luminal ferric iron is reduced to ferrous iron by the ferric reductase, duodenal cytochrome b [20], and is then transported across the apical membrane by a protein called divalent metal transporter-1 (DMT-1) [21], [22]. Iron is subsequently exported from the basolateral cell
Clinical features of hereditary hemochromatosis
In the past, HH was recognized by a constellation of symptoms and physical findings related to significant iron loading in the liver, pancreas, heart, skin, and pituitary [38]. Recently, most patients are asymptomatic, and phlebotomy treatment can be started before the development of significant disease manifestations [3]. This is the result of screening blood tests obtained during a routine health physical, and identification of HFE mutations in individuals during family screening.
Diagnosis of hemochromatosis
The inclusion of iron studies during routine health physicals coupled with the availability of HFE genotyping for familial and population studies has facilitated the detection of HH [2], [3]. It has also led to identification of C282Y homozygotes that lack phenotypic expression. In the past, liver biopsy provided important information for the diagnosis of HH; liver biopsy is no longer essential for the diagnosis. Nonetheless, it still provides an important assessment of liver fibrosis and a
Treatment of hemochromatosis
Once the diagnosis is confirmed, the therapeutic approach for HH is relatively simple but effective. Weekly therapeutic phlebotomy is performed to remove 250 mg of iron with each phlebotomy (each unit of blood contains between 200 and 250 mg of iron depending on the hemoglobin content) [3]. Phlebotomy is to be continued weekly until the patient's serum ferritin level is less than 50 ng/mL and the transferrin saturation is less than 50%.
Family screening for hemochromatosis
Once a proband has been identified and treated, all first-degree relatives should be screened for this familial disorder [2], [3], [45]. Generally, these relatives are screened by measuring fasting transferrin saturation and ferritin levels. Genetic testing can also be performed. If elevated iron studies are detected, or if any relatives are C282Y-C282Y or C282Y-H63D, therapeutic phlebotomy can be initiated, using the previously mentioned guidelines. Children of a proband are often evaluated
Population screening for hemochromatosis
After the discovery of HFE, it was suggested that population screening with genetic testing might be ideal for HFE-related HH. This was because the disorder is common, has a long latent phase before the development of disease manifestations, has simple and effective treatment, and has simple tests for phenotypic markers. Not all C282Y homozygotes, however, have phenotypic expression; this raises questions about the advisability of large-scale population screening. In fact, studies using HFE
Secondary iron overload
Abnormal serum iron studies are common in patients with porphyria cutanea tarda, nonalcoholic steatohepatitis, chronic hepatitis C, and alcoholic liver disease [54], [55], [56], [57], [58], [59]. Up to 50% of patients with these disorders have abnormal serum iron studies. The hepatic iron concentration is typically normal or slightly increased [3], [38]. A detailed discussion of these clinical entities is beyond the scope of this article but has been previously outlined [60].
Relationship of hemochromatosis with hepatocellular carcinoma
HCC occurs in 19% to 24% of HH [61]. Kowdley et al [62] detected HCC in 27% of patients undergoing liver transplantation for hemochromatosis. In fact, this rate increased to 43% when including either dysplasia or HCC. Early studies reported that the likelihood of developing HCC in the setting of HH was increased more than 200-fold [4], [5]. Recent data from a Swedish cohort suggest that the increased risk is closer to 20-fold, however, with an adjusted risk of liver cancer at 10 years of
Risk factors for hepatocellular carcinoma
Most HH patients developing HCC are male, more than 50 years old, and have cirrhosis. Indeed, a review of the literature revealed only 13 cases of HCC in hemochromatosis patients without cirrhosis [68], [69], [70], [71], [72], [73], [74], [75]. The higher the amount and the longer the duration of iron overload the higher the risk of developing cirrhosis and of HCC [76]. Other risk factors for HCC include concomitant infection with hepatitis B or hepatitis C virus [77], and alcoholism and
Clinical presentation and natural history of hepatocellular carcinoma associated with hemochromatosis
Most patients with HH developing HCC are cirrhotic. Unfortunately, the prevalence of cirrhosis in several population cohort studies ranges from 20% to 69% [4], [6], [63]. Among a cohort of Italian patients with HH and cirrhosis, the cumulative survival rates were 75% at 5 years and 47% at 10 years [7]. HCC was responsible for death in 45% of these patients. HCC typically occurs in males in the fifth or sixth decade of life [65], [79], [80]. Up to 36% of cirrhotic HH patients develop HCC during
Pathogenesis of hepatocellular carcinoma associated with hemochromatosis
The principles of hepatic carcinogenesis in the setting of hepatic iron overload are debated. The transformation from normal tissue to neoplasia is a dynamic, multifaceted process that is believed to begin with an initiator or carcinogen that results in altered nuclear base pairs and resultant genetic changes. With cell division, these mutations are propagated and result in potential neoplastic proliferation. Iron may be a direct carcinogen that initiates this sequence of events.
Epidemiologic
Screening-diagnosis of hepatocellular carcinoma
The prognosis of HCC is dismal unless detected at an early stage. Unfortunately, most patients have advanced disease at diagnosis [78], [79], [95], precluding them from potentially curative surgery. Although prospective, randomized trials demonstrating a survival benefit from screening for HCC do not exist, new technology is allowing for the detection of HCC at a much earlier stage.
Historically, screening strategies for HCC have included serologic testing for alpha fetoprotein. The sensitivity
Treatment of hepatocellular carcinoma associated with hereditary hemochromatosis
Surgical intervention, whether partial hepatotectomy or liver transplantation, is the only established curative therapy. Other modalities are considered palliative. Unfortunately, most patients with cirrhosis and HCC are not surgical candidates. Current surgical treatment strategies are based on tumor size, number, and location; presence of vascular invasion; extrahepatic metastasis; overall patient condition; and comorbidity. In general, liver transplantation is the best treatment option for
Prevention of hepatocellular carcinoma in hemochromatosis
Strategies to prevent or detect early HCC in HH patients are being evaluated. Early diagnosis and treatment of HH can significantly reduce the risk of HCC. Although HCC can rarely occur in noncirrhotic patients, most HH patients with HCC have cirrhosis. Every effort should be made to diagnose and treat HH patients with phlebotomy before the development of cirrhosis. Hemochromatosis patients with normal aspartate aminotransferase, age less than 40 years, serum ferritin level less than 1000
Summary
HH is a common inherited disorder of iron metabolism affecting about 1 out of 250 individuals of Northern European decent. Many of these patients do not have evident phenotypic expression and do not develop significant iron loading. Some patients, however, develop progressive iron overload and cirrhosis. These individuals are at risk of developing HCC. Cirrhotics with hemochromatosis should undergo regular screening for HCC. If HCC is identified early, treatment with either resection or liver
References (120)
- et al.
Haemochromatosis in the new millennium
J Hepatol
(2000) Hemochromatosis: diagnosis and management
Gastroenterology
(2001)- et al.
Cancer risk in patients with hereditary hemochromatosis and their first degree relatives
Gastroenterology
(2003) - et al.
Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor
Cell
(1998) - et al.
Molecular medicine and hemochromatosis: at the crossroads
Gastroenterology
(1999) - et al.
A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation
Gastroenterology
(2002) - et al.
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation
Mol Cell
(2000) - et al.
Molecular aspects of iron absorption and HFE expression
Gastroenterology
(2001) - et al.
Intestinal absorption of iron in HFE-1 hemochromatosis: local or systemic process?
J Hepatol
(2004) - et al.
Intestinal iron uptake determined by divalent metal transporter is enhanced in HFE-deficient mice with hemochromatosis
Gastroenterology
(2001)
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis
Lancet
Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload
Gastroenterology
Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains
Gastroenterology
Nonexpressing homozygotes for C282Y hemochromatosis: minority or majority of cases?
Mol Genet Metab
Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA
Lancet
Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis
Gastroenterology
Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection
J Hepatol
Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
Gastroenterology
Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients
Blood Cells Mol Dis
Screening for hemochromatosis
Clin Chim Acta
Measurement of iron status in patients with chronic hepatitis
Gastroenterology
Increased cancer risk in a cohort of 230 patients with hemochromatosis in comparison to matched control patients with non-iron related chronic liver disease
Hepatology
Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases
Gastroenterology
Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis
Gastroenterology
Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver: a case report
Pathol Res Pract
Long-term survival in patients with hereditary hemochromatosis
Gastroenterology
Can large cell change and high proliferative activity predict hepatocellular carcinoma in patients with hereditary hemochromatosis?
Am J Gastroenterol
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival
Hepatology
Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases
Hepatology
p53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis
Gastroenterol
Hepatocellular carcinoma: current surgical management
Semin Oncol
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population
Hepatology
Prospective study of screening for hepatocellular carcinoma in caucasian patients with cirrhosis
J Hepatol
Imaging of hepatocellular carcinoma: a practical approach
Semin Oncol
Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis
N Engl J Med
Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases
J Natl Cancer Inst
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis
Hepatology
Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing
N Engl J Med
A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis
Nat Genet
Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor
Traffic
Pathogenesis of hereditary hemochromatosis: genetics and beyond
Semin Gastrointest Dis
Molecular pathogenesis of iron overload
Gut
EASL international consensus conference on haemochromatosis
J Hepatol
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients
Am J Hum Genet
Disorders of iron metabolism
N Engl J Med
Mechanisms of iron accumulation in hereditary hemochromatosis
Annu Rev Physiol
An iron-regulated ferric reductase associated with the absorption of dietary iron
Science
Cloning and characterization of a mammalian proton-coupled metal-ion transporter
Nature
Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
Nat Genet
Cited by (62)
Iron
2021, Handbook on the Toxicology of Metals: Fifth EditionDisorders of Iron Overload
2018, MacSween's Pathology of the LiverJuvenile hemochromatosis and hepatocellular carcinoma in a patient with a novel mutation in the HJV gene
2017, European Journal of Medical GeneticsIron
2015, Handbook on the Toxicology of Metals: Fourth EditionIron
2014, Handbook on the Toxicology of MetalsHepatocellular carcinoma epidemiology
2014, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :Hereditary hemochromatosis is an autosomal recessive disorder characterized by excessive dietary iron absorption and subsequent deposition in the parenchymal cells of the liver, pancreas, heart, joints, and pituitary gland. Iron overload may eventually lead to cirrhosis and HCC [138]. Early studies reported that the likelihood of developing HCC among persons with hereditary hemochromatosis was increased more than 200-fold [139,140].